Compare Heron Therapeutics Inc (HRTX) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Schwab US Large Cap Growth ETF — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Schwab US Large Cap Growth ETF trades at $36.59 (market cap $65.01B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 955.9× Heron Therapeutics Inc's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| HRTX | SCHG | |
|---|---|---|
Market Cap | $68.01M | $65.01B |
Volume | 1,891,941 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $1.49 | $36.93 |
52-Week Low | $0.27 | $28.10 |
Typical Hold Time | 35 Days | 50 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
SCHG trades at $36.87, down 0.16% with a bullish technical outlook from moving averages but bearish oscillators. The ETF maintains strong growth exposure with low expense ratios, though recent news highlights concentration risks in top holdings. Dividend activity remains minimal with a $0.04 distribution scheduled for September 2026.
Growth ETF positioning favors long-term investors despite near-term overbought signals. Key risks include heavy concentration in megacap tech stocks and potential valuation compression. Analyst sentiment remains positive for strategic allocations to large-cap growth exposure with disciplined entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
